A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, Including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors – Poster Presentation, ASCO 2026
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a Phase 1/2 study of EIK1005, both as a standalone treatment and in combination with Pembrolizumab, targeting advanced solid tumors. The study focuses on patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors. The findings were presented at ASCO 2026, highlighting the potential of EIK1005 in oncology.
Price reaction · baseline $10.84 (2026-05-29 close) · 4 other EIKN headline(s) in the window, move may be shared
day 0 close · peak
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
EIK1005 shows promise as a treatment option.
The study includes advanced solid tumors with specific genetic markers.
Combination therapy with Pembrolizumab may enhance effectiveness.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~24 mo
Minimal dilution risk
Lead asset
EIK1001
Phase 2 · NSCLC
Full Press Release Details
05/30/2026
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, Including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors – Poster Presentation, ASCO 2026
Share
Share on LinkedIn
Frequently Asked Questions
What is the focus of the EIK1005 study?
The study focuses on EIK1005 as a treatment for advanced solid tumors, particularly those with MSI-H or dMMR.
What combination therapy is being tested with EIK1005?
EIK1005 is being tested both as a monotherapy and in combination with Pembrolizumab.
Where was the EIK1005 study presented?
The findings of the EIK1005 study were presented at ASCO 2026.
What types of tumors are included in the study?
The study includes participants with advanced solid tumors, specifically MSI-H and dMMR tumors.